Insulin Degludec/Liraglutide/Metformin combination's effect on Type 2 Diabetes intensification under investigation

Type 2 Diabetes (T2D) often necessitates treatment intensification as the disease progresses, with existing therapies sometimes failing to achieve optimal glycemic control or presenting undesirable side effects. Combination therapies are frequently explored to leverage synergistic mechanisms and improve patient outcomes. Insulin degludec (a long-acting insulin analog) and liraglutide (a GLP-1 receptor agonist) offer distinct yet complementary approaches to glucose regulation, making their combination with metformin a logical next step for patients needing more robust glycemic management.

This trial investigates the effect of insulin degludec in combination with liraglutide and metformin (at least 1500 mg daily or maximum tolerated dose) in subjects with Type 2 Diabetes requiring treatment intensification. Participants received Insulin degludec/liraglutide (IDegLira) via subcutaneous injection once daily for 26 weeks. The initial dose was 16 dose steps, equivalent to 16 units insulin degludec and 0.6 mg liraglutide. The study is conducted across Africa, Asia, Europe, and North America.

No specific results or findings are available in the provided abstract for this clinical trial. The text outlines the study design and intervention protocol but does not report any outcomes, statistical data, or efficacy/safety measurements from the investigation. Therefore, no quantitative findings or p-values can be reported at this time.